<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191931</url>
  </required_header>
  <id_info>
    <org_study_id>CR2P00113</org_study_id>
    <nct_id>NCT01191931</nct_id>
  </id_info>
  <brief_title>Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)</brief_title>
  <acronym>PHS-02</acronym>
  <official_title>Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Medical Diagnostics s.a.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Medical Diagnostics s.a.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design:

      -The study will be a phase I like study to assess the extent to which prostate HistoScanning
      (PHS, the index test) can identify and characterize foci of prostate cancer when compared to
      histological samples harvested during radical prostatectomy (the reference test). The study
      will comprise 3 steps: first, defining the most suitable method for matching the TRUS
      (TransRectalUltrasonography) to histology (step 1); second, refining the algorithms (training
      set); third, verification of the PHS performances (test set).

      Study objectives:

        -  Primary Objective:

             -  To evaluate the extent to which PHS can discriminate between malignant lesions of
                the prostate versus non-malignant tissue in 3D RF TRUS data using radical
                prostatectomy histological step sectioning as the reference test.

        -  Secondary Objectives:

             -  To adapt and refine PHS tissue characterisation algorithms using RF data that were
                previously developed using grey-level data as input.

             -  To assess the accuracy of PHS in predicting the volume of prostate cancers
                determined by histology.

             -  To assess the ability of PHS to rule in or rule out the presence of cancer &gt; or =
                0.5 cc and of &gt; or = 0.2 cc as determined by histology.

             -  To evaluate the ability to discriminate primary Gleason pattern 4 and 5 versus 3 or
                less in tumours &gt; or = 0.5 cc and &gt; or = 0.2 cc.

             -  To assess the ability of PHS to correctly risk stratify patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">52</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>prostate cancer</arm_group_label>
    <description>Patients with histologically proven prostate cancer (positive biopsy) and who are planned to undergo radical prostatectomy.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      paraffin blocks of prostate specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically proven prostate cancer (positive biopsy) and who are planned
        to undergo radical prostatectomy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: &gt;or=18 year-old

          -  Histologically (positive biopsy) proven prostate cancer with primary and secondary
             Gleason patterns attributed.

          -  Patient planned to undergo radical prostatectomy

          -  Prostate cancer is deemed to be organ confined (T1-T2, Nx or No, Mx or Mo)

          -  No prior treatment for prostate cancer, including any type of hormonal therapy

          -  No major calcification is noted during the TRUS (i.e. (Diameter &gt;or=5 mm, spread all
             over the prostate or blocking to much of the ultrasound signal).

          -  Patient willing to give written informed consent

        Exclusion Criteria:

          -  Patients who are either unsuitable or unwilling to enter the study or to proceed to
             surgical investigation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Bleiberg, MD</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ-Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olomouc Hospital</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>H-1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust, Charing Cross Hospital</name>
      <address>
        <city>Hammersmith</city>
        <state>London</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital (UCLH)</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir R, Nir D, Michielsen D, Bleiberg H, Egevad L, Emberton M. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int. 2008 Feb;101(3):293-8. Epub 2007 Oct 8.</citation>
    <PMID>17922870</PMID>
  </reference>
  <reference>
    <citation>Braeckman J, Autier P, Soviany C, Nir R, Nir D, Michielsen D, Treurnicht K, Jarmulowicz M, Bleiberg H, Govindaraju S, Emberton M. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int. 2008 Dec;102(11):1560-5. doi: 10.1111/j.1464-410X.2008.07878.x. Epub 2008 Aug 14.</citation>
    <PMID>18710457</PMID>
  </reference>
  <reference>
    <citation>Lucidarme O, Akakpo JP, Granberg S, Sideri M, Levavi H, Schneider A, Autier P, Nir D, Bleiberg H; Ovarian HistoScanning Clinical Study Group. A new computer-aided diagnostic tool for non-invasive characterisation of malignant ovarian masses: results of a multicentre validation study. Eur Radiol. 2010 Aug;20(8):1822-30. doi: 10.1007/s00330-010-1750-6. Epub 2010 Mar 20.</citation>
    <PMID>20306081</PMID>
  </reference>
  <reference>
    <citation>Vaes E, Manchanda R, Nir R, Nir D, Bleiberg H, Autier P, Menon U, Robert A. Mathematical models to discriminate between benign and malignant adnexal masses: potential diagnostic improvement using ovarian HistoScanning. Int J Gynecol Cancer. 2011 Jan;21(1):35-43. doi: 10.1097/IGC.0b013e3182000528.</citation>
    <PMID>21330829</PMID>
  </reference>
  <reference>
    <citation>Salomon G, Spethmann J, Beckmann A, Autier P, Moore C, Durner L, Sandmann M, Haese A, Schlomm T, Michl U, Heinzer H, Graefen M, Steuber T. Accuracy of HistoScanning™ for the prediction of a negative surgical margin in patients undergoing radical prostatectomy. BJU Int. 2013 Jan;111(1):60-6. doi: 10.1111/j.1464-410X.2012.11396.x. Epub 2012 Aug 9.</citation>
    <PMID>22882794</PMID>
  </reference>
  <results_reference>
    <citation>Simmons LA, Autier P, Zát'ura F, Braeckman J, Peltier A, Romic I, Stenzl A, Treurnicht K, Walker T, Nir D, Moore CM, Emberton M. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™). BJU Int. 2012 Jul;110(1):28-35. doi: 10.1111/j.1464-410X.2011.10734.x. Epub 2011 Nov 17.</citation>
    <PMID>22093966</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2010</study_first_posted>
  <last_update_submitted>October 26, 2012</last_update_submitted>
  <last_update_submitted_qc>October 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

